Uncover key drivers, emerging technologies, and competitive movements shaping the hormone refractory prostate cancer market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Hormone Refractory Prostate Cancer Market between 2026 and 2030?
The hormone refractory prostate cancer market size has experienced significant expansion in recent years. This market is projected to expand from $8.12 billion in 2025 to $8.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. Historically, this growth was driven by factors such as the increasing incidence of advanced prostate cancer, the broad adoption of androgen deprivation therapy, enhanced availability of chemotherapy agents, the increasing application of PSA-based disease monitoring, and the development of oncology care infrastructure.
The market size for hormone refractory prostate cancer is anticipated to experience robust growth in the coming years. It is projected to expand to $13.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This expansion during the forecast period is driven by factors such as the increasing creation of targeted therapies, escalating clinical trial involvement in castration-resistant prostate cancer, an increasing need for personalized oncology solutions, the broadening of immuno-oncology pipelines, and greater healthcare spending on cancer treatments. Significant trends during this period involve the wider acceptance of precision oncology therapies, a rise in the application of combination drug regimens, the increasing incorporation of biomarker-based treatment choices, the expansion of immunotherapy applications for advanced prostate cancer, and an intensified focus on tailored treatment pathways.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Hormone Refractory Prostate Cancer Market?
Increasing funding directed towards cancer research is projected to fuel the expansion of the hormone-refractory prostate cancer market in the future. This investment in cancer research encompasses financial and resource backing aimed at promoting novel methods for detecting, treating, and preventing cancer. The surge in cancer research funding stems from the escalating worldwide prevalence of cancer, necessitating more potent and focused therapeutic options. Funding for cancer research stimulates advancements in addressing hormone-refractory prostate cancer, facilitating the development of sophisticated therapies like radioligand treatments and hormone inhibitors. Additionally, it finances clinical studies and investigations into biomarkers, thereby improving the accuracy and effectiveness of treatments. As an illustration, in August 2024, the Cancer Research Institute (CRI), a US-based nonprofit organization focused on advancing immunotherapy research, allocated approximately $22.8 million during the 2023–2024 fiscal year, supporting 64 new grants for researchers affiliated with 42 institutions spanning seven countries. Consequently, increased investment in cancer research is propelling the expansion of the hormone-refractory prostate cancer market.
What Segments Are Included Within The Hormone Refractory Prostate Cancer Market?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
Which Trends Are Shaping Activity Within The Hormone Refractory Prostate Cancer Market?
Leading companies in the hormone-refractory prostate cancer market are concentrating on developing advanced therapies, such as intravenous radioligand therapy, to enhance survival rates for patients with resistant forms of the disease. Intravenous radioligand therapy is a targeted treatment that utilizes radioactive molecules linked to ligands to identify and bind to cancer-specific markers, internally destroying cancer cells while preserving surrounding healthy tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical corporation, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received approval from the Food and Drug Administration (FDA). This treatment is designed for earlier administration in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable to delay chemotherapy. The expanded indication, based on the Phase III PSMAfore trial, approximately triples the eligible patient population and showed that Pluvicto reduced the risk of radiographic progression or death by 59% and more than doubled median radiographic progression-free survival compared to a change in ARPI. Pluvicto is the first targeted radioligand therapy approved for use before chemotherapy in this setting, offering a new treatment option that delays disease progression with a favorable safety profile.
Who Are The Primary Competitors In The Global Hormone Refractory Prostate Cancer Market?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Hormone Refractory Prostate Cancer Market?
North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Hormone Refractory Prostate Cancer Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp
Browse Through More Reports Similar to the Global Hormone Refractory Prostate Cancer Market 2026, By The Business Research Company
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Market Report 2026
Prostate Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model